Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis


Stott, KE ORCID: 0000-0001-7079-7957, Pertinez, H, Sturkenboom, MGG, Boeree, MJ, Aarnoutse, R, Ramachandran, G, Requena-Mendez, A, Peloquin, C, Koegelenberg, CFN, Alffenaar, JWC et al (show 5 more authors) (2018) Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73 (9). pp. 2305-2313.

[img] Text
Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.pdf - Published version
Download (491kB)

Abstract

<h4>Objectives</h4>The objectives of this study were to explore inter-study heterogeneity in the pharmacokinetics (PK) of orally administered rifampicin, to derive summary estimates of rifampicin PK parameters at standard dosages and to compare these with summary estimates for higher dosages.<h4>Methods</h4>A systematic search was performed for studies of rifampicin PK published in the English language up to May 2017. Data describing the Cmax and AUC were extracted. Meta-analysis provided summary estimates for PK parameter estimates at standard rifampicin dosages. Heterogeneity was assessed by estimation of the I2 statistic and visual inspection of forest plots. Summary AUC estimates at standard and higher dosages were compared graphically and contextualized using preclinical pharmacodynamic (PD) data.<h4>Results</h4>Substantial heterogeneity in PK parameters was evident and upheld in meta-regression. Treatment duration had a significant impact on the summary estimates for rifampicin PK parameters, with Cmax 8.98 mg/L (SEM 2.19) after a single dose and 5.79 mg/L (SEM 2.14) at steady-state dosing, and AUC 72.56 mg·h/L (SEM 2.60) and 38.73 mg·h/L (SEM 4.33) after single and steady-state dosing, respectively. Rifampicin dosages of at least 25 mg/kg are required to achieve plasma PK/PD targets defined in preclinical studies.<h4>Conclusions</h4>Vast inter-study heterogeneity exists in rifampicin PK parameter estimates. This is not explained by the available modifying variables. The recommended dosage of rifampicin should be increased to improve efficacy. This study provides an important point of reference for understanding rifampicin PK at standard dosages as efforts to explore higher dosing strategies continue in this field.

Item Type: Article
Uncontrolled Keywords: Humans, Tuberculosis, Rifampin, Antibiotics, Antitubercular, Administration, Oral, Adult, Female, Male, Healthy Volunteers
Depositing User: Symplectic Admin
Date Deposited: 28 Jan 2019 14:40
Last Modified: 19 Jan 2023 01:05
DOI: 10.1093/jac/dky152
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3031906
Dimensions
Altmetric
CORE (COnnecting REpositories)